APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mycoplasma Testing in Clinical

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Mycoplasma Testing in Clinical Market Outlook and Growth Opportunities 2026

5 June 2026208 pages

Choose your research edition.

Industry ResearchMycoplasma Testing in Clinical Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Mycoplasma Testing in Clinical Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Mycoplasma Testing in Clinical Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mycoplasma Testing in Clinical Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Mycoplasma Testing in Clinical Market Analysis and Forecast 2026-2032181 pages · $4,950 USD

Market perspective

The global Mycoplasma Testing in Clinical market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Mycoplasma Testing in Clinical is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Mycoplasma Testing in Clinical is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Mycoplasma Testing in Clinical is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Mycoplasma Testing in Clinical market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Mycoplasma Testing in Clinical market include Charles River Laboratories International, Thermo Fisher Scientific, SGS, Bionique Testing Laboratories, WuXi AppTec, Labcorp, IDEXX BioAnalytics, WiCell and Creative Biogene, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Mycoplasma Testing in Clinical market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Mycoplasma Testing in Clinical and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Mycoplasma Testing in Clinical revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Mycoplasma Testing in Clinical market.

Mycoplasma Testing in Clinical Segment by Company

Charles River Laboratories International

Thermo Fisher Scientific

SGS

Bionique Testing Laboratories

WuXi AppTec

Labcorp

IDEXX BioAnalytics

WiCell

Creative Biogene

Eurofins Scientific

Hylabs

JOINN Laboratories

Shimadzu Diagnostics

CellSafe

FullHope Biomedical

Syngene International

Beyotime

CTI Cert

Shenke Bio

Mycoplasma Testing in Clinical Segment by Type

Culture-based Mycoplasma Detection

PCR/qPCR Mycoplasma Detection

Others

Mycoplasma Testing in Clinical Segment by Application

Hospitals

Clinical Laboratories

Public Health Institutions

Third-Party Medical Testing Centers

Others

Mycoplasma Testing in Clinical Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Mycoplasma Testing in Clinical status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Mycoplasma Testing in Clinical key companies, revenue, market share, and recent developments.

3. To split the Mycoplasma Testing in Clinical breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Mycoplasma Testing in Clinical market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Mycoplasma Testing in Clinical significant trends, drivers, influence factors in global and regions.

6. To analyze Mycoplasma Testing in Clinical competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mycoplasma Testing in Clinical market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mycoplasma Testing in Clinical and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mycoplasma Testing in Clinical.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Mycoplasma Testing in Clinical industry.

Chapter 3: Detailed analysis of Mycoplasma Testing in Clinical company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Mycoplasma Testing in Clinical in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Mycoplasma Testing in Clinical in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Mycoplasma Testing in Clinical Industry Trends Table 2. Mycoplasma Testing in Clinical Industry Drivers Table 3. Mycoplasma Testing in Clinical Industry Opportunities and Challenges Table 4. Mycoplasma Testing in Clinical Industry Restraints Table 5. Global Mycoplasma Testing in Clinical Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Mycoplasma Testing in Clinical Revenue Share by Company (2021-2026) Table 7. Global Mycoplasma Testing in Clinical Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Mycoplasma Testing in Clinical Key Company Manufacturing Base & Headquarters Table 9. Global Mycoplasma Testing in Clinical Company, Product Type & Application Table 10. Global Mycoplasma Testing in Clinical Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Mycoplasma Testing in Clinical by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Culture-based Mycoplasma Detection Table 15. Significant Companies of PCR/qPCR Mycoplasma Detection Table 16. Significant Companies of Others Table 17. Global Mycoplasma Testing in Clinical Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Mycoplasma Testing in Clinical Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Mycoplasma Testing in Clinical Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Mycoplasma Testing in Clinical Sales Value Share by Type (2021-2026) Table 21. Global Mycoplasma Testing in Clinical Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospitals Table 23. Significant Companies of Clinical Laboratories Table 24. Significant Companies of Public Health Institutions Table 25. Significant Companies of Third-Party Medical Testing Centers Table 26. Significant Companies of Others Table 27. Global Mycoplasma Testing in Clinical Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Mycoplasma Testing in Clinical Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Mycoplasma Testing in Clinical Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Mycoplasma Testing in Clinical Sales Value Share by Application (2021-2026) Table 31. Global Mycoplasma Testing in Clinical Sales Value Share by Application (2027-2032) Table 32. Global Mycoplasma Testing in Clinical Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Mycoplasma Testing in Clinical Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Mycoplasma Testing in Clinical Sales Value Share by Region (2021-2026) Table 35. Global Mycoplasma Testing in Clinical Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Mycoplasma Testing in Clinical Sales Value Share by Region (2027-2032) Table 37. Global Mycoplasma Testing in Clinical Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Mycoplasma Testing in Clinical Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Mycoplasma Testing in Clinical Sales Value Market Share by Country (2021-2026) Table 40. Global Mycoplasma Testing in Clinical Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Mycoplasma Testing in Clinical Sales Value Market Share by Country (2027-2032) Table 42. Charles River Laboratories International Company Information Table 43. Charles River Laboratories International Business Overview Table 44. Charles River Laboratories International Mycoplasma Testing in Clinical Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Charles River Laboratories International Mycoplasma Testing in Clinical Product Portfolio Table 46. Charles River Laboratories International Recent Development Table 47. Thermo Fisher Scientific Company Information Table 48. Thermo Fisher Scientific Business Overview Table 49. Thermo Fisher Scientific Mycoplasma Testing in Clinical Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Thermo Fisher Scientific Mycoplasma Testing in Clinical Product Portfolio Table 51. Thermo Fisher Scientific Recent Development Table 52. SGS Company Information Table 53. SGS Business Overview Table 54. SGS Mycoplasma Testing in Clinical Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. SGS Mycoplasma Testing in Clinical Product Portfolio Table 56. SGS Recent Development Table 57. Bionique Testing Laboratories Company Information Table 58. Bionique Testing Laboratories Business Overview Table 59. Bionique Testing Laboratories Mycoplasma Testing in Clinical Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Bionique Testing Laboratories Mycoplasma Testing in Clinical Product Portfolio Table 61. Bionique Testing Laboratories Recent Development Table 62. WuXi AppTec Company Information Table 63. WuXi AppTec Business Overview Table 64. WuXi AppTec Mycoplasma Testing in Clinical Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. WuXi AppTec Mycoplasma Testing in Clinical Product Portfolio Table 66. WuXi AppTec Recent Development Table 67. Labcorp Company Information Table 68. Labcorp Business Overview Table 69. Labcorp Mycoplasma Testing in Clinical Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Labcorp Mycoplasma Testing in Clinical Product Portfolio Table 71. Labcorp Recent Development Table 72. IDEXX BioAnalytics Company Information Table 73. IDEXX BioAnalytics Business Overview Table 74. IDEXX BioAnalytics Mycoplasma Testing in Clinical Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. IDEXX BioAnalytics Mycoplasma Testing in Clinical Product Portfolio Table 76. IDEXX BioAnalytics Recent Development Table 77. WiCell Company Information Table 78. WiCell Business Overview Table 79. WiCell Mycoplasma Testing in Clinical Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. WiCell Mycoplasma Testing in Clinical Product Portfolio Table 81. WiCell Recent Development Table 82. Creative Biogene Company Information Table 83. Creative Biogene Business Overview Table 84. Creative Biogene Mycoplasma Testing in Clinical Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Creative Biogene Mycoplasma Testing in Clinical Product Portfolio Table 86. Creative Biogene Recent Development Table 87. Eurofins Scientific Company Information Table 88. Eurofins Scientific Business Overview Table 89. Eurofins Scientific Mycoplasma Testing in Clinical Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Eurofins Scientific Mycoplasma Testing in Clinical Product Portfolio Table 91. Eurofins Scientific Recent Development Table 92. Hylabs Company Information Table 93. Hylabs Business Overview Table 94. Hylabs Mycoplasma Testing in Clinical Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Hylabs Mycoplasma Testing in Clinical Product Portfolio Table 96. Hylabs Recent Development Table 97. JOINN Laboratories Company Information Table 98. JOINN Laboratories Business Overview Table 99. JOINN Laboratories Mycoplasma Testing in Clinical Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. JOINN Laboratories Mycoplasma Testing in Clinical Product Portfolio Table 101. JOINN Laboratories Recent Development Table 102. Shimadzu Diagnostics Company Information Table 103. Shimadzu Diagnostics Business Overview Table 104. Shimadzu Diagnostics Mycoplasma Testing in Clinical Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Shimadzu Diagnostics Mycoplasma Testing in Clinical Product Portfolio Table 106. Shimadzu Diagnostics Recent Development Table 107. CellSafe Company Information Table 108. CellSafe Business Overview Table 109. CellSafe Mycoplasma Testing in Clinical Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. CellSafe Mycoplasma Testing in Clinical Product Portfolio Table 111. CellSafe Recent Development Table 112. FullHope Biomedical Company Information Table 113. FullHope Biomedical Business Overview Table 114. FullHope Biomedical Mycoplasma Testing in Clinical Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. FullHope Biomedical Mycoplasma Testing in Clinical Product Portfolio Table 116. FullHope Biomedical Recent Development Table 117. Syngene International Company Information Table 118. Syngene International Business Overview Table 119. Syngene International Mycoplasma Testing in Clinical Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. Syngene International Mycoplasma Testing in Clinical Product Portfolio Table 121. Syngene International Recent Development Table 122. Beyotime Company Information Table 123. Beyotime Business Overview Table 124. Beyotime Mycoplasma Testing in Clinical Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 125. Beyotime Mycoplasma Testing in Clinical Product Portfolio Table 126. Beyotime Recent Development Table 127. CTI Cert Company Information Table 128. CTI Cert Business Overview Table 129. CTI Cert Mycoplasma Testing in Clinical Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 130. CTI Cert Mycoplasma Testing in Clinical Product Portfolio Table 131. CTI Cert Recent Development Table 132. Shenke Bio Company Information Table 133. Shenke Bio Business Overview Table 134. Shenke Bio Mycoplasma Testing in Clinical Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 135. Shenke Bio Mycoplasma Testing in Clinical Product Portfolio Table 136. Shenke Bio Recent Development Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Mycoplasma Testing in Clinical Product Image Figure 2. Global Mycoplasma Testing in Clinical Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mycoplasma Testing in Clinical Market Size (2021-2032) & (US$ Million) Figure 4. Global Mycoplasma Testing in Clinical Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Culture-based Mycoplasma Detection Image Figure 8. PCR/qPCR Mycoplasma Detection Image Figure 9. Others Image Figure 10. Global Mycoplasma Testing in Clinical Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Mycoplasma Testing in Clinical Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Mycoplasma Testing in Clinical Sales Value Share by Type (2021-2032) Figure 13. Hospitals Image Figure 14. Clinical Laboratories Image Figure 15. Public Health Institutions Image Figure 16. Third-Party Medical Testing Centers Image Figure 17. Others Image Figure 18. Global Mycoplasma Testing in Clinical Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Mycoplasma Testing in Clinical Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Mycoplasma Testing in Clinical Sales Value Share by Application (2021-2032) Figure 21. Global Mycoplasma Testing in Clinical Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Mycoplasma Testing in Clinical Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Mycoplasma Testing in Clinical Sales Value (2021-2032) & (US$ Million) Figure 24. North America Mycoplasma Testing in Clinical Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Mycoplasma Testing in Clinical Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Mycoplasma Testing in Clinical Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Mycoplasma Testing in Clinical Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Mycoplasma Testing in Clinical Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Mycoplasma Testing in Clinical Sales Value (2021-2032) & (US$ Million) Figure 30. South America Mycoplasma Testing in Clinical Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Mycoplasma Testing in Clinical Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Mycoplasma Testing in Clinical Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Culture-based Mycoplasma Detection
  • PCR/qPCR Mycoplasma Detection
  • Others
Applications
  • Hospitals
  • Clinical Laboratories
  • Public Health Institutions
  • Third-Party Medical Testing Centers
  • Others
Companies covered
  • Charles River Laboratories International
  • Thermo Fisher Scientific
  • SGS
  • Bionique Testing Laboratories
  • WuXi AppTec
  • Labcorp
  • IDEXX BioAnalytics
  • WiCell
  • Creative Biogene
  • Eurofins Scientific
  • Hylabs
  • JOINN Laboratories
  • Shimadzu Diagnostics
  • CellSafe
  • FullHope Biomedical
  • Syngene International
  • Beyotime
  • CTI Cert
  • Shenke Bio

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Mycoplasma Testing in Clinical Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Mycoplasma Testing in Clinical Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Mycoplasma Testing in Clinical Market Dynamics
  1. 2.1 Mycoplasma Testing in Clinical Industry Trends
  2. 2.2 Mycoplasma Testing in Clinical Industry Drivers
  3. 2.3 Mycoplasma Testing in Clinical Industry Opportunities and Challenges
  4. 2.4 Mycoplasma Testing in Clinical Industry Restraints
3 Mycoplasma Testing in Clinical Market by Company
  1. 3.1 Global Mycoplasma Testing in Clinical Company Revenue Ranking in 2025
  2. 3.2 Global Mycoplasma Testing in Clinical Revenue by Company (2021-2026)
  3. 3.3 Global Mycoplasma Testing in Clinical Company Ranking (2024-2026)
  4. 3.4 Global Mycoplasma Testing in Clinical Company Manufacturing Base and Headquarters
  5. 3.5 Global Mycoplasma Testing in Clinical Company Product Type and Application
  6. 3.6 Global Mycoplasma Testing in Clinical Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Mycoplasma Testing in Clinical Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Mycoplasma Testing in Clinical Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Mycoplasma Testing in Clinical Market by Type
  1. 4.1 Mycoplasma Testing in Clinical Type Introduction
  2. 4.1.1 Culture-based Mycoplasma Detection
  3. 4.1.2 PCR/qPCR Mycoplasma Detection
  4. 4.1.3 Others
  5. 4.2 Global Mycoplasma Testing in Clinical Sales Value by Type
  6. 4.2.1 Global Mycoplasma Testing in Clinical Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Mycoplasma Testing in Clinical Sales Value by Type (2021-2032)
  8. 4.2.3 Global Mycoplasma Testing in Clinical Sales Value Share by Type (2021-2032)
5 Mycoplasma Testing in Clinical Market by Application
  1. 5.1 Mycoplasma Testing in Clinical Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinical Laboratories
  4. 5.1.3 Public Health Institutions
  5. 5.1.4 Third-Party Medical Testing Centers
  6. 5.1.5 Others
  7. 5.2 Global Mycoplasma Testing in Clinical Sales Value by Application
  8. 5.2.1 Global Mycoplasma Testing in Clinical Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Mycoplasma Testing in Clinical Sales Value by Application (2021-2032)
  10. 5.2.3 Global Mycoplasma Testing in Clinical Sales Value Share by Application (2021-2032)
6 Mycoplasma Testing in Clinical Regional Value Analysis
  1. 6.1 Global Mycoplasma Testing in Clinical Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Mycoplasma Testing in Clinical Sales Value by Region (2021-2032)
  3. 6.2.1 Global Mycoplasma Testing in Clinical Sales Value by Region: 2021-2026
  4. 6.2.2 Global Mycoplasma Testing in Clinical Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Mycoplasma Testing in Clinical Sales Value (2021-2032)
  7. 6.3.2 North America Mycoplasma Testing in Clinical Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Mycoplasma Testing in Clinical Sales Value (2021-2032)
  10. 6.4.2 Europe Mycoplasma Testing in Clinical Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Mycoplasma Testing in Clinical Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Mycoplasma Testing in Clinical Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Mycoplasma Testing in Clinical Sales Value (2021-2032)
  16. 6.6.2 South America Mycoplasma Testing in Clinical Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Mycoplasma Testing in Clinical Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Mycoplasma Testing in Clinical Sales Value Share by Country, 2025 VS 2032
7 Mycoplasma Testing in Clinical Country-level Value Analysis
  1. 7.1 Global Mycoplasma Testing in Clinical Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Mycoplasma Testing in Clinical Sales Value by Country (2021-2032)
  3. 7.2.1 Global Mycoplasma Testing in Clinical Sales Value by Country (2021-2026)
  4. 7.2.2 Global Mycoplasma Testing in Clinical Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Mycoplasma Testing in Clinical Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Mycoplasma Testing in Clinical Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Mycoplasma Testing in Clinical Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Charles River Laboratories International
  2. 8.1.1 Charles River Laboratories International Company Information
  3. 8.1.2 Charles River Laboratories International Business Overview
  4. 8.1.3 Charles River Laboratories International Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Charles River Laboratories International Mycoplasma Testing in Clinical Product Portfolio
  6. 8.1.5 Charles River Laboratories International Recent Developments
  7. 8.2 Thermo Fisher Scientific
  8. 8.2.1 Thermo Fisher Scientific Company Information
  9. 8.2.2 Thermo Fisher Scientific Business Overview
  10. 8.2.3 Thermo Fisher Scientific Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Thermo Fisher Scientific Mycoplasma Testing in Clinical Product Portfolio
  12. 8.2.5 Thermo Fisher Scientific Recent Developments
  13. 8.3 SGS
  14. 8.3.1 SGS Company Information
  15. 8.3.2 SGS Business Overview
  16. 8.3.3 SGS Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  17. 8.3.4 SGS Mycoplasma Testing in Clinical Product Portfolio
  18. 8.3.5 SGS Recent Developments
  19. 8.4 Bionique Testing Laboratories
  20. 8.4.1 Bionique Testing Laboratories Company Information
  21. 8.4.2 Bionique Testing Laboratories Business Overview
  22. 8.4.3 Bionique Testing Laboratories Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bionique Testing Laboratories Mycoplasma Testing in Clinical Product Portfolio
  24. 8.4.5 Bionique Testing Laboratories Recent Developments
  25. 8.5 WuXi AppTec
  26. 8.5.1 WuXi AppTec Company Information
  27. 8.5.2 WuXi AppTec Business Overview
  28. 8.5.3 WuXi AppTec Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  29. 8.5.4 WuXi AppTec Mycoplasma Testing in Clinical Product Portfolio
  30. 8.5.5 WuXi AppTec Recent Developments
  31. 8.6 Labcorp
  32. 8.6.1 Labcorp Company Information
  33. 8.6.2 Labcorp Business Overview
  34. 8.6.3 Labcorp Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Labcorp Mycoplasma Testing in Clinical Product Portfolio
  36. 8.6.5 Labcorp Recent Developments
  37. 8.7 IDEXX BioAnalytics
  38. 8.7.1 IDEXX BioAnalytics Company Information
  39. 8.7.2 IDEXX BioAnalytics Business Overview
  40. 8.7.3 IDEXX BioAnalytics Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  41. 8.7.4 IDEXX BioAnalytics Mycoplasma Testing in Clinical Product Portfolio
  42. 8.7.5 IDEXX BioAnalytics Recent Developments
  43. 8.8 WiCell
  44. 8.8.1 WiCell Company Information
  45. 8.8.2 WiCell Business Overview
  46. 8.8.3 WiCell Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  47. 8.8.4 WiCell Mycoplasma Testing in Clinical Product Portfolio
  48. 8.8.5 WiCell Recent Developments
  49. 8.9 Creative Biogene
  50. 8.9.1 Creative Biogene Company Information
  51. 8.9.2 Creative Biogene Business Overview
  52. 8.9.3 Creative Biogene Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Creative Biogene Mycoplasma Testing in Clinical Product Portfolio
  54. 8.9.5 Creative Biogene Recent Developments
  55. 8.10 Eurofins Scientific
  56. 8.10.1 Eurofins Scientific Company Information
  57. 8.10.2 Eurofins Scientific Business Overview
  58. 8.10.3 Eurofins Scientific Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eurofins Scientific Mycoplasma Testing in Clinical Product Portfolio
  60. 8.10.5 Eurofins Scientific Recent Developments
  61. 8.11 Hylabs
  62. 8.11.1 Hylabs Company Information
  63. 8.11.2 Hylabs Business Overview
  64. 8.11.3 Hylabs Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Hylabs Mycoplasma Testing in Clinical Product Portfolio
  66. 8.11.5 Hylabs Recent Developments
  67. 8.12 JOINN Laboratories
  68. 8.12.1 JOINN Laboratories Company Information
  69. 8.12.2 JOINN Laboratories Business Overview
  70. 8.12.3 JOINN Laboratories Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  71. 8.12.4 JOINN Laboratories Mycoplasma Testing in Clinical Product Portfolio
  72. 8.12.5 JOINN Laboratories Recent Developments
  73. 8.13 Shimadzu Diagnostics
  74. 8.13.1 Shimadzu Diagnostics Company Information
  75. 8.13.2 Shimadzu Diagnostics Business Overview
  76. 8.13.3 Shimadzu Diagnostics Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Shimadzu Diagnostics Mycoplasma Testing in Clinical Product Portfolio
  78. 8.13.5 Shimadzu Diagnostics Recent Developments
  79. 8.14 CellSafe
  80. 8.14.1 CellSafe Company Information
  81. 8.14.2 CellSafe Business Overview
  82. 8.14.3 CellSafe Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  83. 8.14.4 CellSafe Mycoplasma Testing in Clinical Product Portfolio
  84. 8.14.5 CellSafe Recent Developments
  85. 8.15 FullHope Biomedical
  86. 8.15.1 FullHope Biomedical Company Information
  87. 8.15.2 FullHope Biomedical Business Overview
  88. 8.15.3 FullHope Biomedical Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  89. 8.15.4 FullHope Biomedical Mycoplasma Testing in Clinical Product Portfolio
  90. 8.15.5 FullHope Biomedical Recent Developments
  91. 8.16 Syngene International
  92. 8.16.1 Syngene International Company Information
  93. 8.16.2 Syngene International Business Overview
  94. 8.16.3 Syngene International Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Syngene International Mycoplasma Testing in Clinical Product Portfolio
  96. 8.16.5 Syngene International Recent Developments
  97. 8.17 Beyotime
  98. 8.17.1 Beyotime Company Information
  99. 8.17.2 Beyotime Business Overview
  100. 8.17.3 Beyotime Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Beyotime Mycoplasma Testing in Clinical Product Portfolio
  102. 8.17.5 Beyotime Recent Developments
  103. 8.18 CTI Cert
  104. 8.18.1 CTI Cert Company Information
  105. 8.18.2 CTI Cert Business Overview
  106. 8.18.3 CTI Cert Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  107. 8.18.4 CTI Cert Mycoplasma Testing in Clinical Product Portfolio
  108. 8.18.5 CTI Cert Recent Developments
  109. 8.19 Shenke Bio
  110. 8.19.1 Shenke Bio Company Information
  111. 8.19.2 Shenke Bio Business Overview
  112. 8.19.3 Shenke Bio Mycoplasma Testing in Clinical Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Shenke Bio Mycoplasma Testing in Clinical Product Portfolio
  114. 8.19.5 Shenke Bio Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst